Compile Data Set for Download or QSAR
Report error Found 322 Enz. Inhib. hit(s) with all data for entry = 11653
TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM50557844(CHEMBL4748025 | WO2021067859, Compound I-8B)
Affinity DataIC50: 0.275nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM50557845(CHEMBL4756236 | WO2021067859, Compound I-9A)
Affinity DataIC50: 0.351nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM50557847(CHEMBL4749714 | WO2021067859, Compound I-19)
Affinity DataIC50: 0.425nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM50557849(CHEMBL4751524 | WO2021067859, Compound IV-9)
Affinity DataIC50: 0.595nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM50557848(CHEMBL4777764 | WO2021067859, Compound I-21)
Affinity DataIC50: 0.601nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM50557848(CHEMBL4777764 | WO2021067859, Compound I-21)
Affinity DataIC50: 0.639nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637051(WO2021067859, Compound I-24 | WO2021067859, Compou...)
Affinity DataIC50: 0.669nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637061(WO2021067859, Compound IV-2 | WO2021067859, Compou...)
Affinity DataIC50: 0.677nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637061(WO2021067859, Compound IV-2 | WO2021067859, Compou...)
Affinity DataIC50: 0.791nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637080(WO2021067859, Compound I-12B)
Affinity DataIC50: 0.809nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637082(WO2021067859, Compound IV-7)
Affinity DataIC50: 1.10nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637071(WO2021067859, Compound I-17)
Affinity DataIC50: 1.12nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637092(WO2021067859, Compound I-27)
Affinity DataIC50: 1.13nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637072(WO2021067859, Compound 4)
Affinity DataIC50: 1.20nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637095(WO2021067859, Compound I-30A)
Affinity DataIC50: 1.36nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637088(WO2021067859, Compound 5)
Affinity DataIC50: 1.49nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637053(WO2021067859, Compound I-7A)
Affinity DataIC50: 1.5nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637077(WO2021067859, Compound I-23)
Affinity DataIC50: 1.59nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637067(WO2021067859, Compound I-16)
Affinity DataIC50: 1.61nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637049(WO2021067859, Compound I-6)
Affinity DataIC50: 1.61nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637087(WO2021067859, Compound I-8A)
Affinity DataIC50: 1.65nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637066(WO2021067859, Compound I-18 | WO2021067859, Compou...)
Affinity DataIC50: 1.68nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637078(WO2021067859, Compound III-1)
Affinity DataIC50: 1.79nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637059(WO2021067859, Compound IV-4)
Affinity DataIC50: 1.80nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637093(WO2021067859, Compound I-28A)
Affinity DataIC50: 1.81nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637079(WO2021067859, Compound IV-5)
Affinity DataIC50: 2.04nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637090(WO2021067859, Compound I-26B)
Affinity DataIC50: 2.23nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637081(WO2021067859, Compound IV-10)
Affinity DataIC50: 2.30nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637100(WO2021067859, Compound I-34)
Affinity DataIC50: 2.32nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM593464(US11578066, Compound I-156 | N-(5-chloropyridin-3-...)
Affinity DataIC50: 2.53nMAssay Description:Table 13: The compounds disclosed herein, in particular those of Formula (I), were synthesized according to methods disclosed in PCT/US2020/066439, p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637091(WO2021067859, Compound 6)
Affinity DataIC50: 2.54nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637085(WO2021067859, Compound I-15)
Affinity DataIC50: 2.64nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637062(WO2021067859, Compound IV-3)
Affinity DataIC50: 3.35nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637076(WO2021067859, Compound I-22)
Affinity DataIC50: 3.36nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637066(WO2021067859, Compound I-18 | WO2021067859, Compou...)
Affinity DataIC50: 3.78nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM593418(US11578066, Compound I-109 | N-(5-chloropyridin-3-...)
Affinity DataIC50: 3.92nMAssay Description:Table 13: The compounds disclosed herein, in particular those of Formula (I), were synthesized according to methods disclosed in PCT/US2020/066439, p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637083(WO2021067859, Compound IV-6)
Affinity DataIC50: 4.06nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637054(WO2021067859, Compound I-7B)
Affinity DataIC50: 4.13nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM593316(US11578066, Compound I-4 | N-(3-chlorophenyl)-N-((...)
Affinity DataIC50: 4.20nMAssay Description:Table 13: The compounds disclosed herein, in particular those of Formula (I), were synthesized according to methods disclosed in PCT/US2020/066439, p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM593315(US11578066, Compound I-3 | N-(3-chlorophenyl-N-((5...)
Affinity DataIC50: 4.40nMAssay Description:Table 13: The compounds disclosed herein, in particular those of Formula (I), were synthesized according to methods disclosed in PCT/US2020/066439, p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637089(WO2021067859, Compound I-26A)
Affinity DataIC50: 4.57nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM593347(US11578066, Compound I-36 | N-(3-chlorophenyl)-N-(...)
Affinity DataIC50: 5nMAssay Description:Table 13: The compounds disclosed herein, in particular those of Formula (I), were synthesized according to methods disclosed in PCT/US2020/066439, p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637102(WO2021067859, Compound I-36)
Affinity DataIC50: 5.22nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM593531(US11578066, Compound I-223 | N-({5-[5-(difluoromet...)
Affinity DataIC50: 5.63nMAssay Description:Table 13: The compounds disclosed herein, in particular those of Formula (I), were synthesized according to methods disclosed in PCT/US2020/066439, p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM593485(US11578066, Compound I-177 | N-[5-(difluoromethoxy...)
Affinity DataIC50: 6nMAssay Description:Table 13: The compounds disclosed herein, in particular those of Formula (I), were synthesized according to methods disclosed in PCT/US2020/066439, p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM593533(US11578066, Compound I-225 | N-({5-[5-(difluoromet...)
Affinity DataIC50: 6.01nMAssay Description:Table 13: The compounds disclosed herein, in particular those of Formula (I), were synthesized according to methods disclosed in PCT/US2020/066439, p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM637052(WO2021067859, Compound I-5)
Affinity DataIC50: 6.68nMAssay Description:Table 14: The compounds disclosed herein, in particular those of Formula (II), were synthesized according to methods disclosed in WO2021067859, which...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM593523(US11578066, Compound I-215 | N-({5-[5-(difluoromet...)
Affinity DataIC50: 6.75nMAssay Description:Table 13: The compounds disclosed herein, in particular those of Formula (I), were synthesized according to methods disclosed in PCT/US2020/066439, p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM593465(US11578066, Compound I-157 | N-[5-(difluoromethoxy...)
Affinity DataIC50: 6.93nMAssay Description:Table 13: The compounds disclosed herein, in particular those of Formula (I), were synthesized according to methods disclosed in PCT/US2020/066439, p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetHistone deacetylase 6(Human)
Tenaya Therapeutics

US Patent
LigandPNGBDBM593466(US11578066, Compound I-158 | N-(5-chloropyridin-3-...)
Affinity DataIC50: 7.22nMAssay Description:Table 13: The compounds disclosed herein, in particular those of Formula (I), were synthesized according to methods disclosed in PCT/US2020/066439, p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

Displayed 1 to 50 (of 322 total ) | Next | Last >>
Jump to: